U.S. markets close in 3 hours 3 minutes

NeutriSci International Inc. (NRXCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.05330.0000 (0.00%)
As of 03:50PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0533
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0533 - 0.0533
52 Week Range0.0510 - 0.2666
Avg. Volume5,272
Market Cap8.854M
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0090
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NRXCF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more

    NeutriSci Announces Successful Completion of R&D in Preparation for Launch of Its Functional Mushroom Product Line

    VANCOUVER, BC / ACCESSWIRE / November 30, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company")(TSXV:NU)(OTCQB:NRXCF)(FSE:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that is has successfully completed the R&D of a newly developed effervescent functional mushroom tablet product for online sales in Europe and North America.

  • CNW Group

    NeutriSci Provides Production Update and Partner Progress

    NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), an innovative technology company developing products, licencing, IP, and technology for B2B partnerships and the nutraceutical industry, is pleased to provide the following update.


    NeutriSci Receives Additional Purchase Order and Deposit from Tabletz Distribution Partner

    VANCOUVER, BC / ACCESSWIRE / September 22, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to announce that it has received an additional order from Tabletz LLC.